{
  "trial_id": "NCT03331562",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, ECOG performance status, histologically or cytologically confirmed pancreatic adenocarcinoma, prior chemotherapy, organ function (serum corrected calcium, phosphorus levels), pregnancy status (for females of childbearing potential), use of contraception (for both male and female participants), history of immunodeficiency, history of active TB, hypersensitivity to pembrolizumab or paricalcitol, prior anti-cancer monoclonal antibody treatment, prior chemotherapy or radiation therapy, additional malignancy status, CNS metastases status, autoimmune disease history, history of pneumonitis, active infection status, psychiatric or substance abuse disorders, prior anti-PD-1/PD-L1/PD-L2 therapy, serum vitamin D level, use of strong CYP3A inhibitors, HIV status, Hepatitis B or C status, cardiac arrhythmias, live vaccine receipt within 30 days.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "ECOG Performance Status",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "histologically or cytologically confirmed pancreatic adenocarcinoma",
        "prior chemotherapy",
        "organ function (serum corrected calcium, phosphorus levels)",
        "pregnancy status (for females of childbearing potential)",
        "use of contraception (for both male and female participants)",
        "history of immunodeficiency",
        "history of active TB",
        "hypersensitivity to pembrolizumab or paricalcitol",
        "prior anti-cancer monoclonal antibody treatment",
        "prior chemotherapy or radiation therapy",
        "additional malignancy status",
        "CNS metastases status",
        "autoimmune disease history",
        "history of pneumonitis",
        "active infection status",
        "psychiatric or substance abuse disorders",
        "prior anti-PD-1/PD-L1/PD-L2 therapy",
        "serum vitamin D level",
        "use of strong CYP3A inhibitors",
        "HIV status",
        "Hepatitis B or C status",
        "cardiac arrhythmias",
        "live vaccine receipt within 30 days."
      ]
    },
    "processed-gen-response": "Age, sex, ECOG performance status, histologically or cytologically confirmed pancreatic adenocarcinoma, prior chemotherapy, organ function (serum corrected calcium, phosphorus levels), pregnancy status (for females of childbearing potential), use of contraception (for both male and female participants), history of immunodeficiency, history of active TB, hypersensitivity to pembrolizumab or paricalcitol, prior anti-cancer monoclonal antibody treatment, prior chemotherapy or radiation therapy, additional malignancy status, CNS metastases status, autoimmune disease history, history of pneumonitis, active infection status, psychiatric or substance abuse disorders, prior anti-PD-1/PD-L1/PD-L2 therapy, serum vitamin D level, use of strong CYP3A inhibitors, HIV status, Hepatitis B or C status, cardiac arrhythmias, live vaccine receipt within 30 days."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Histological or Cytological Confirmation of Pancreatic Adenocarcinoma, Prior Chemotherapy Response, Serum Corrected Calcium, Phosphorus Levels, Baseline Tumor Biopsy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "ECOG Performance Status",
          "ECOG Performance Status"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Histological or Cytological Confirmation of Pancreatic Adenocarcinoma",
        "Prior Chemotherapy Response",
        "Serum Corrected Calcium",
        "Phosphorus Levels",
        "Baseline Tumor Biopsy"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Histological or Cytological Confirmation of Pancreatic Adenocarcinoma, Prior Chemotherapy Response, Serum Corrected Calcium, Phosphorus Levels, Baseline Tumor Biopsy"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Prior Chemotherapy, Prior Radiation Therapy, Prior Surgery, Histological or Cytological Confirmation of Pancreatic Adenocarcinoma, Metastatic Disease Status, Best Response to First-Line Chemotherapy, Serum Corrected Calcium Value, Phosphorus Levels, Performance Status at Baseline.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "ECOG Performance Status",
          "ECOG Performance Status"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Prior Chemotherapy",
        "Prior Radiation Therapy",
        "Prior Surgery",
        "Histological or Cytological Confirmation of Pancreatic Adenocarcinoma",
        "Metastatic Disease Status",
        "Best Response to First-Line Chemotherapy",
        "Serum Corrected Calcium Value",
        "Phosphorus Levels",
        "Performance Status at Baseline"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Prior Chemotherapy, Prior Radiation Therapy, Prior Surgery, Histological or Cytological Confirmation of Pancreatic Adenocarcinoma, Metastatic Disease Status, Best Response to First-Line Chemotherapy, Serum Corrected Calcium Value, Phosphorus Levels, Performance Status at Baseline."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "age, sex, race, ethnicity, ECOG performance status, histological type of pancreatic adenocarcinoma, number and location of metastatic sites, prior chemotherapy regimens, best response to first-line chemotherapy, serum corrected calcium value, phosphorus levels, vitamin D level.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "ECOG Performance Status",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "histological type of pancreatic adenocarcinoma",
        "number and location of metastatic sites",
        "prior chemotherapy regimens",
        "best response to first-line chemotherapy",
        "serum corrected calcium value",
        "phosphorus levels",
        "vitamin D level."
      ]
    },
    "processed-gen-response": "age, sex, race, ethnicity, ECOG performance status, histological type of pancreatic adenocarcinoma, number and location of metastatic sites, prior chemotherapy regimens, best response to first-line chemotherapy, serum corrected calcium value, phosphorus levels, vitamin D level."
  }
}